Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022912 | 0.90 | P2RY14 (0.33) | NR1H2CTSLCTSBCSNK2A1 | |
| SCHEMBL30396372 | 0.77 | USP30 (0.38) | NR1H2 | |
| SCHEMBL23956770 | 0.77 | USP30 (0.38) | NR1H2 | |
| SCHEMBL30853473 | 0.76 | ALDH1A1 (0.49) | NR1H2 | |
| SCHEMBL1201914 | 0.76 | ALDH1A1 (0.49) | NR1H2 | |
| SCHEMBL23930133 | 0.74 | ATR (0.36) | NR1H2 | |
| SCHEMBL30023439 | 0.74 | ATR (0.36) | NR1H2 | |
| SCHEMBL23930218 | 0.74 | TBK1 (0.36) | NR1H2CSNK2A1 | |
| SCHEMBL30023425 | 0.74 | TBK1 (0.36) | NR1H2CSNK2A1 | |
| SCHEMBL23930269 | 0.72 | MMP12 (0.37) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2025-12-02 | — | — | US | disclosed |
| CN-115397822-B | CBP/EP300 inhibitors and uses thereof | 南京药石科技股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20230159497-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-115397822-A | CBP/EP300 inhibitors and uses thereof | 南京药石科技股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159497-A1 | CBP/EP300 INHIBITOR AND USE THEREOF | EP300, CREBBP, BPTF | NR1H2 258/4885CTSL 3629/4885CTSB 2897/4885 |
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | EP300, CREBBP, BPTF | NR1H2 258/4885CTSL 3629/4885CTSB 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.